Research and Markets: Gain an Insight into the Financial Performance of the Pharmaceutical Company - Bristol-Myers Squibb.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c57258) has announced the addition of the Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. Ltd report: Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were : Performance, Products, Pipeline and Potential to their offering. Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. In the midst Adv. 1. in the midst - the middle or central part or point; "in the midst of the forest"; "could he walk out in the midst of his piece?" midmost of a long-term strategic reinvention of itself, can BMS BMS abbr. Bachelor of Marine Science carry on if the generic challenge to its leading product Plavix is successful? Notwithstanding this threat, BMS has a full pipeline with some exciting blockbuster products, but none due to reach their full potential for some years. It could all be about timing... The company is going through a transitional period, whereby many older products have seen considerable declines in sales due to generic competition, whilst newer products are establishing themselves in the market place. This period of transition has been made more difficult due to a long running dispute with Apotex concerning Plavix, BMS's top selling product. The decision of the Court - due soon - regarding Plavix will be the major determining factor in BMS's future. Recent speculation suggests BMS and sanofi-aventis will be successful, however, the saga has already seen Peter Dolan, the company's chief executive for five years, leave the company and has led to rumours of a merger between BMS and sanofi-aventis. SIGNIFICANT POTENTIAL In order to counter these problems, BMS's has been refreshing its product portfolio, adopting a strategy of increased R&D investment despite decreased income. To this end, BMS's research to sales ratio has increased from 12.2% in 2003, to 17.1% in 2006. Higher levels of expenditure have reaped dividends for the company with five new products launched between 2005 and 2006. Orencia, Sprycel, Emsam, Atripla and Baraclude signify the first stages of BMS's new direction and profile. Within the pipeline, BMS has clearly established key areas of focus, most notably in the field of oncology. The company believes this is the therapeutic area with the greatest unmet medical need and consequently has established a robust pipeline containing novel candidate drugs and new indications for its key products. Ipilimumab, ixabepilone and Javlor have all reached late-stage trials and have demonstrated efficacy in a number of cancer types, offering similar versatility and sales to Erbitux in the future. This new strategic analysis report Bristol-Myers Squibb: Performance, Products, Pipeline and Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. The report is updated on a quarterly basis. Topics Covered Latest Results Executive Summary Therapeutic Area Focus R&D Pipeline Cardio Vascular And Metabolic Diseases Slv319 Virology Neuroscience Oncology Imunology Appendix 1 - Financial Performance Appendix 2 - Key Corporate Events Appendix 3 - Key Agreements Appendix 4 - Infrastructure Appendix 5 - Key Pharmaceutical Subsidiaries / Joint Ventures Appendix 6 - Product Index Index of Tables Index of Charts Companies Mentioned * Adnexus Therapeutics * Aspen Pharmacare/Emcure Pharmaceuticals * AstraZeneca * Biocon * Celltrion Inc * Chiron Corporation Chiron Corporation was a multinational biotechnology firm based in Emeryville, California that was acquired by Novartis International AG on April 20 2006. It had offices and facilities in eighteen countries on five continents. * Dainippon Sumitomo Pharma * Domantis Inc * Elan Corporation Plc * Elixir elixir /elix·ir/ (e-lik´ser) a clear, sweetened, alcohol-containing, usually hydroalcoholic liquid containing flavoring substances and sometimes active medicinal ingredients. e·lix·ir n. Pharmaceuticals * Exelixis Inc * Gilead Sciences Gilead Sciences NASDAQ: GILD is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. Inc * GPC Biotech GPC Biotech (also referred to as GPCbiotech and GPC-Biotech) is a German biopharmaceutical company. The company's mission statement reads "... to discover, develop and commercialize new anticancer drugs. Inc * ImClone Systems ImClone Systems Incorporated (NASDAQ: IMCL) is a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology. It was founded in 1984 and is headquartered in New York City. It is traded on the NASDAQ stock exchange under the symbol IMCL. * Intra-Cellular Therapies Inc (ICT (1) (Information and Communications Technology) An umbrella term for the information technology field. See IT. (2) (International Computers and Tabulators) See ICL. 1. (testing) ICT - In Circuit Test. ) * Lexicon Genetics Incorporated * Medarex Inc * Medivir * Merck Sante SAS (1) (SAS Institute Inc., Cary, NC, www.sas.com) A software company that specializes in data warehousing and decision support software based on the SAS System. Founded in 1976, SAS is one of the world's largest privately held software companies. See SAS System. * Nerviano Medical Sciences * Otsuka/Taiho Pharmaceutical Co Ltd * Pfizer * Pierre Fabre Medicament me·dic·a·ment n. An agent that promotes recovery from injury or ailment; a medicine. medicament a medicinal agent. * sanofi-aventis * Shionogi * Solvay * Sunesis Pharmaceuticals Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecular therapeutics for oncology and other unmet medical needs. Founded in 1998, Sunesis filed and completed an IPO in 2005. For more information visit http://www.researchandmarkets.com/reports/c57258 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion